Novel treatment approaches are needed to overcome innate and acquired mechanisms of
resistance to current anticancer therapies in cancer cells and the tumour immune …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy that is
characterized by early metastasis, low resectability, high recurrence, and therapy resistance …

Simple Summary In recent years, many studies have shown the importance of TAM kinases
in both normal and neoplastic cells. In this review, we present and discuss the role of the …

Trogocytosis is a fast, cell–cell contact-dependent uptake of membrane patches and
associated molecules by one cell from another. Here, we report our investigation of …

The TAM family of receptor tyrosine kinases is implicated in multiple distinct oncogenic
signaling pathways. However, to date, there are no FDA-approved small molecule inhibitors …

Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide. Although
considerable advances in CRC treatment have been achieved, effective treatment …

Tyro3 is a member of the TAM subfamily of receptor tyrosine kinases alongside Axl and
MerTK, which are activated by homologous ligands Gas6 and protein S. The TAMs activate …

Pancreatic cancer (PC) is an aggressive malignancy with few treatment options, and
improved treatment strategies are urgently required. TYRO3, a member of the TAM receptor …

G-749 is an FLT3 kinase inhibitor that was originally developed as a treatment for acute
myeloid leukemia. Some FLT3 kinase inhibitors are dual kinase inhibitors that inhibit the …

Pancreatic cancer is expected to become the second leading cause of cancer-related death
within the next few years. Current therapeutic strategies have limited effectiveness and …